Restek Seeks Approval to Import Rare Controlled Substances
Published Date: 3/4/2026
Notice
Summary
Restek Corporation wants to become an official importer of some controlled substances, including Amineptine and Mesocarb. People and companies involved with these drugs can share their thoughts or ask for a hearing by April 3, 2026. This move could affect how these substances are brought into the U.S., but no direct costs are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Importer Registration to Import Listed Controlled Substances
On February 11, 2026, Restek Corporation applied to be registered as an importer of the listed basic classes of controlled substances (examples include Amineptine and Mesocarb, and many other Schedule I and II substances). The company says it plans to import these substances to manufacture exempted certified reference materials; interested parties may submit comments or request a hearing by April 3, 2026.
Import Authorization Excludes Finished Dosage Forms
The DEA states authorization for this registration will not extend to importing FDA-approved or non-approved finished dosage forms for commercial sale. Approval will be granted only when the registrant's business activity is consistent with 21 U.S.C. 952(a)(2).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-04298 — Extension of a Currently Approved Information Collection: Special Bond of Indemnity by Purchaser of United States Savings Bonds/Notes Involved in a Chain Letter Scheme
The Treasury is extending a form that helps people get refunds if they bought U.S. Savings Bonds through a tricky chain letter scheme. This affects individuals who need to fill out a special bond of indemnity form, which takes about 8 minutes to complete. Comments on this process are open until May 4, 2026, and there’s no new cost involved—just a smooth continuation of the current system.
Next: 2026-04300 — Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection; Corporate Whistleblower Awards Pilot Program Online Intake Portal
The Department of Justice is launching a new online portal for the Corporate Whistleblower Awards Pilot Program, making it easier for whistleblowers to submit tips. This change affects anyone who wants to report corporate wrongdoing and could speed up the process while protecting their info. The DOJ is asking for public feedback by May 4, 2026, to make sure the system works well and isn’t a hassle.